pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
PATH · news · pharmadog
← back to PATH
News mentioning PATH
310
stories
21d
Novo drops ‘Nordisk’ moniker, turns bull toward future in corporate rebrand
biospace
21d
AstraZeneca’s newly approved cancer pill fails late-stage study, blocking path to bigger market
biospace
21d
Scholar Rock secures first FDA approval for muscle-targeting rare disease drug
biospace
21d
Opinion: Restoring public trust in science doesn’t have a simple solution. That’s OK
stat
21d
5 drugmakers chasing Merck and Moderna in the cancer vaccine race
biospace
24d
Cullinan, Taiho showcase 6-month survival benefit in phase 3 trial for advanced lung cancer
fiercebiotech
24d
Beyond clinical endpoints: Rethinking ALS drug development through disease biology
fiercebiotech
24d
Novartis’ board faces investor scrutiny after M&A misfires and R&D flops
biospace
25d
Tyra shares slip as bladder cancer responses fall short of investor expectations
biospace
25d
A booming business on Wall Street would love more biotechs to quietly die
biopharma dive
25d
Tyra disappoints investors with bladder cancer data
biopharma dive
26d
Key research behind orexin and narcolepsy wins Lasker Award
endpoints
26d
Compass posts positive psilocybin data; Solstice makes $225M debut
endpoints
26d
Telemedicine company offers GLP-1s for addiction
stat
26d
NodThera, a decade-old NLRP3 player, plans Phase 3 and a rebrand
endpoints
26d
Steady stream of crossover rounds stock biotech's IPO pipeline
biospace
27d
Moonwalk reloads with $70M and new RNAi prospects for obesity
biopharma dive
27d
Novartis RNA drug falls short in rare muscle disease study
biopharma dive
27d
A breakthrough pancreatic cancer drug won approval. They still struggle to access it
stat
27d
Reeling from past failures, Parkinson's pipeline enters 'era of diversification'
biospace
27d
Novartis stock slides as centerpiece of $12B Avidity buyout flunks ‘crucial’ phase 3 test
fiercebiotech
Sep 4, 26
Biotech is back, with H1 progress smoothing glide path through end of year: Truist
biospace
Sep 4, 26
AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study
biospace
Sep 3, 26
HHS flip-flops on disability lawsuit
stat
Sep 3, 26
STAT+: FDA pilot offers generative AI medical devices a path to patients before they are authorized
stat
Sep 2, 26
STAT+: Ultragenyx drug to treat Angelman syndrome, a rare disease, fails late-stage trial
stat
Sep 2, 26
Biopharma reverse mergers rise 1,600% in Q3 to rival IPOs
biospace
Sep 1, 26
Alumis’ TYK2 drug fails in key lupus study
biopharma dive
Sep 1, 26
Alumis' TYK2 drug fails in lupus trial; CEO sees 'clear path forward'
endpoints
Sep 1, 26
Alumis crushed by midstage lupus flop but plots path to phase 3 for TYK2 inhibitor
fiercebiotech
← prev
page 3 of 11
next →
